Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro

Cancer Investigation

Volumn 25, Issue 4, 2007, Pages 240-248

  Hsu, Faye Yuan Yi ^a   Zhao, Yi ^b   Anderson, W French ^a   Johnston, Patrick B ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Mayo Clinic   (United States)

Author keywords

ALCL; Lymphoma; siRNA

Indexed keywords

DOXORUBICIN; HYBRID PROTEIN; NUCLEOPHOSMIN ANAPLASTIC LYMPHOMA KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL LOSS; CELL PROLIFERATION; CHEMOSENSITIVITY; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; GENE REPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LEUKEMIA CELL LINE; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 5; DOWN-REGULATION; HUMANS; LYMPHOMA, LARGE-CELL; PROTEIN-TYROSINE KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC;

EID: 34347396141     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701206372     Document Type: Article

References (37)

1. Stein, H.; Mason, D.Y.; Gerdes, J.; O'Connor, N.; Wainscoat, J.; et al.: The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985, 66, 848-858.
2. Falini, B.; Bigerna, B.; Fizzotti, M.; Pulford, K.; Pileri, S.A.; et al. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am. J. Pathol. 1998, 153, 875-886.
3. Iwahara, T.; Fujimoto, J.; Wen, D.; Cupples, R.; Bucay, N.; et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997, 14, 439-449
4. Ruchatz, H.; Coluccia, A.M.; Stano, P.; Marchesi, E.; Gambacorti-Passerini, C. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. Exp. Hematol. 2003, 31, 309-315.
5. Ma, Z.; Cools, J.; Marynen, P.; Cui, X.; Siebert, R.; et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 2000, 95, 2144-2149.
6. Hernandez, L.; Pinyol, M.; Hernandez, S.; Bea, S.; Pulford, K.; et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 1999, 94, 3265-3268.
7. Hernandez, L.; Bea, S.; Bellosillo, B.; Pinyol, M.; Falini, B.; et al. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFGALK( XL) chimeric gene with transforming activity. Am. J. Pathol. 2002, 160, 1487-1494.
8. Cools, J.; Wlodarska, I.; Somers, R.; Mentens, N.; Pedeutour, F.; et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatorymyofibroblastic tumor. Genes Chromosomes Cancer 2002, 34, 354-362.
9. Colleoni, G.W.; Bridge, J.A.; Garicochea, B.; Liu, J.; Filippa, D.A.; et al. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am. J. Pathol. 2000, 156, 781-789.
10. Rosenwald, A.; Ott, G.; Pulford, K.; Katzenberger, T.; Kuhl, J.; et al t(1;2)(q21;p23) and t(2;3)(p23;q21): two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma. Blood 1999, 94, 362-364.
11. Tort, F.; Pinyol, M.; Pulford, K.; Roncador, G.; Hernandez, L.; et al. Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab. Invest. 2001, 81, 419-426.
12. Trinei, M.; Lanfrancone, L.; Campo, E.; Pulford, K.; Mason, D.Y.; et al. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res. 2000, 60, 793-798.
13. Wlodarska, I.; De Wolf-Peeters, C.; Falini, B.; Verhoef, G.; Morris, S.W.; et al. The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma. Blood 1998, 92, 2688-2695.
14. Yee, H.T.; Ponzoni, M.; Merson, A.; Goldstein, M.; Scarpa, A.; et al. Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease. Blood 1996, 87, 1081-1088.
15. Borer, R.A.; Lehner, C.F.; Eppenberger, H.M.; Nigg, E.A. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989, 56, 379-390.
16. Bischof, D.; Pulford, K.; Mason, D.Y.; Morris, S.W. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphomaassociated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol. Cell Biol. 1997, 17, 2312-2325.
17. Bai, R.Y.; Dieter, P.; Peschel, C.; Morris, S.W.; Duyster, J. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol. Cell Biol. 1998, 18, 6951-6961.
18. Zamo, A.; Chiarle, R.; Piva, R.; Howes, J.; Fan, Y.; et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002, 21, 1038-1047.
19. Zhang, Q.; Raghunath, P.N.; Xue, L.; Majewski, M.; Carpentieri, D.F.; et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J. Immunol. 2002, 168, 466-474.
20. Bai, R.Y.; Ouyang, T.; Miething, C.; Morris, S.W.; Peschel, C.; Duyster, J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000, 96, 4319-4327.
21. Slupianek, A.; Nieborowska-Skorska, M.; Hoser, G.; Morrione, A.; Majewski, M.; et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 2001, 61, 2194-2199.
22. Cussac, D.; Greenland, C.; Roche, S.; Bai, R.Y.; Duyster, J.; et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic largecell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 2004, 103, 1464-1471.
23. Fujimoto, J.; Shiota, M.; Iwahara, T.; Seki, N.; Saton, H.; et al. Characterization of th transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc. Natl. Acad. Sci. 1996, 93, 4181-4186.
24. Kuefer, M.U.; Look, A.T.; Pulford, K.; Behm, F.G.; Pattengale, P.K.; et al. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 1997, 90, 2901-2910.
25. Chiarle, R.; Gong, J.Z.; Guasparri, I.; Pesci, A.; Cai, J.; et al. NPMALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003, 101, 1919-1927.
26. Miething, C.;Grundler, R.; Fend, F.; Hoepfl, J.; Mugler, C.; et al. The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model. Oncogene 2003, 22, 4642-4647.
27. Ergin, M.; Denning, M.F.; Izban, K.F.; Amin, H.M.; Martinez, R.L.; et al. Inhibition of tyrosine kinase activity induces caspasedependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein. Exp. Hematol. 2001, 29, 1082-1090.
28. Hubinger, G.; Wehnes, E.; Xue, L.; Morris, S.W.; Maurer, U. Hammerhead ribozyme-mediated cleavage of the fusion transcript NPM-ALK associated with anaplastic large-cell lymphoma. Exp. Hematol. 2003, 31, 226-233.
29. Ritter, U.; Damm-Welk, C.; Fuchs, U.; Bohle, R.M.; Borkhardt, A.; Woessmann, W. Design and evaluation of chemically synthesized siRNA targeting the NPM-ALK fusion site in anaplastic large cell lymphoma (ALCL). Oligonucleotides 2003, 13, 365-373.
30. Druker, B.J. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002, 21, 8541-8546.
31. Wohlbold, L.; Van Der Kuip, H.; Miething, C.; Vornlocher, H.P.; Knabbe, C.; et al. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 2003, 102 (6), 2236-2239.
32. Scherr, M.; Battmer, K.; Winkler, T.; Heidenreich, O.; Ganser, A.; Eder, M. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 2003, 101, 1566-1569.
33. Greenland, C.; Touriol, C.; Chevillard, G.; Morris, S.W.; Bai, R.; et al. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis. Oncogene 2001, 20, 7386-7397.
34. Adam, P.; Katzenberger, T.; Seeberger, H.; Gattenlohner, S.; Wolf, J.; et al. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Am. J. Surg. Pathol. 2003, 27, 1473-1476.
35. Wasik, M.A. Expression of anaplastic lymphoma kinase in non-Hodgkin's lymphomas and other malignant neoplasms. biological, diagnostic, and clinical implications. Am. J. Clin. Pathol. 2002, 118 (Suppl), S81-92.
36. Piva, R.; et al. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 2006, 107, 689-697.
37. Marzec, M.; et al. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab. Invest. 2005, 85, 1544-1554.